Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

11,350articles mentioning institutions

22,378institution mentions

9,137distinct institutions extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted institutions

Showing 6,361–6,420 of 9,137, ordered by supporting articles. Choose a institution to see its evidence.

New York City1 New York University1 New York University Grossman School of Medicine1 New Zealand Medical Journal1 New centres1 Newcastle Medical School1 Newcastle Mitochondrial cohort1 Newcastle North Tyneside 2 Research Ethics Committee1 Newcastle Upon Tyne Hospitals NHS Trust1 Newcastle upon Tyne National Health Service1 Newcastle-upon-Tyne Foundation Trust1 Newfoundland and Labrador Health Research Ethics Board1 NexImmune1 Next Steps Longitudinal Study1 NextBiomedical Co.1 Ng Teng Fong General Hospital1 Niagara Health1 Nielsen et al1 Nigeria Implementation Science Alliance–Model Innovation and Research Centres1 Nigerian centre1 Nigest Elleni Mohammed Memorial Comprehensive Specialised Hospital1 Nightingale Study1 Ninewells Hospital1 Ninewells Teaching Hospital1 Ningxia Eye Hospital1 Ninth People’s Hospital1 Nippon Medical School1 Nishimoto et al1 Nishizawa et al.1 Nivel Panel Samen Sterk1 Nivel Primary Care Database1 Nobile-Orazio et al1 Noldus Information Technology BV1 Noldus Information Technology BV, NL1 Nor-Work from Norway1 Nordic Biosciences1 Nordic Occupational Cancer Study1 Nordpred Prediction Model1 Norfolk and Norwich Hospital1 North Al-Khuwair Health Center1 North American Hepatitis B Research Network1 North American Neuroendocrine Tumor Society1 North American academic institutions1 North American radiation oncology societies1 North East and Yorkshire Genomic Laboratory Hub1 North London NHS Foundation Trust1 North Tyneside General Hospital1 North Tyneside General Hospital NTGH1 North West Ambulance Service1 North West Genomic Laboratory Hub1 North West Multi-center Research Ethics Committee1 North West School of Emergency Medicine1 North York General Hospital1 Northeast Medical College Hospital1 Northern Finland Birth Cohort Eye Study1 Northern General Hospital1 Northern General Hospitals’ Emergency Departments1 Northern Illinois University1 Northern Ireland Ambulance Service1 Northern Ireland Barrett’s Register1

View all 9,137 institutions on one page

Articles mentioning institutions

11,350 articles · page 312 of 946

521 Correlative analysis of a phase I study of autologous activated NK Cells ± rhIL-15 in children and young adults with refractory solid tumors

jitc · abstract · 2025-11-04 · 2 matching annotations

93.7%

National Cancer Institute NCI rhIL-15 solid tumors relapsed/refractory solid tumors NK cell immunotherapies cyclophosphamide

…his study was approved by the Institutional Review Board of the National Cancer Institute (NCI) at the NIH, approval number 13-C-0152, and was conducted …

522 A clinical study on iNeo-Vac-P01: a personalized neoantigen immunotherapy for postoperative recurrence prevention in pancreatic cancer

jitc · abstract · 2025-11-04 · 2 matching annotations

95.3%

Zhejiang Provincial People’s Hospital iNeo-Vac-P01 pancreatic ductal adenocarcinoma (PDAC)

…n-label, single-arm clinical trial ( NCT04810910), conducted at Zhejiang Provincial People’s Hospital, enrolled PDAC patients who initiated treatment with iNeo-Vac-P…

536 Phase 1 trial of tumor-infiltrating lymphocyte (TIL) therapy in recurrent glioblastoma: A single-center experience using cells derived from primary surgical specimens

jitc · abstract · 2025-11-04 · 2 matching annotations

97.5%

Second Affiliated Hospital of Soochow University The Second Affiliated Hospital of Soochow University cyclophosphamide hydroxychloroquine Glioblastoma left frontal lobe glioblastoma sintilimab Innovent GB

… open-label, nonrandomized clinical trial ( NCT04943913) at the Second Affiliated Hospital of Soochow University to evaluate the safety and efficacy of TIL therapy in recurrent…

537 Targeting diffuse intrinsic pontine glioma with IL-7Rα-enhanced B7-H3 (CMD03) chimeric antigen receptor T cell: preliminary results from phase 1 clinical trial

jitc · abstract · 2025-11-04 · 2 matching annotations

97.0%

Chulalongkorn University Cancer Immunol Immunother dexamethasone CMD03 anakinra B7-H3 Diffuse intrinsic pontine glioma (DIPG)B7-H3-targeting DIPG

…DIPG ( NCT06221553). Approval was granted by the IRB committee, Chulalongkorn University (COA#1647/2024). Dose levels include 1×107, 3×107, and 1×108 CA…

54 Development and characterization of cytokine-based classifiers to predict response to immunotherapy using an ex vivo live tumor fragment platform

jitc · abstract · 2025-11-04 · 2 matching annotations

79.9%

Voabil et al.NCT05478538 αPD-1 αPD-L1 αCTLA-4

…ovide external validation of a weighted classifier published by Voabil et al.1 for predicting response to PD-1 blockade. Additionally, we tra…

552 Feasibility and tolerability of a CD4 re-directed chimeric antigen receptor T cell therapy (CD4CAR) in hematological malignancies: Initial results from multi-institutional first-in-human (FIH) trials

jitc · abstract · 2025-11-04 · 2 matching annotations

98.3%

Indiana University University of Miami FDA AML bendamustine acute myeloid leukemias chronic myelomonocytic leukemia fludarabine/cyclophosphamide TCM venetoclax+3 more

…CT06197672Ethics Approval The study obtained ethics approval by Indiana University and University of Miami IRB and participants gave informed cons…

553 A phase I clinical trial of allogeneic NKT cells expressing a CD19-specific CAR in patients with relapsed or refractory B cell malignancies: an interim analysis

jitc · abstract · 2025-11-04 · 2 matching annotations

94.1%

Baylor College of Medicine BCM graft-versus-host disease B cell malignancies IL-15 ALL-1 NHL-2 ALL-3

…al This study was approved by the Institutional Review Board at Baylor College of Medicine (BCM; H-44526).…

556 Transposon-based BAFF CAR-T cells (LMY-920) for treatment of non-hodgkin lymphoma (NHL), chronic lymphocytic lymphoma (CLL) and multiple myeloma (MM)

jitc · abstract · 2025-11-04 · 2 matching annotations

92.2%

Case Comprehensive Cancer Center Cleveland Clinic’s Institutional Review Board fludarabine lymphoma myeloma cyclophosphamide LMY-920 systemic lupus erythematosus MM DLBCL+2 more

…06916767Ethics Approval The study obtained ethics approval from Case Comprehensive Cancer Center, Cleveland Clinic’s Institutional Review Board (24-424/MOD01553…

560 Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in bilateral lung transplantation: case series

jitc · abstract · 2025-11-04 · 2 matching annotations

97.1%

Northwestern Memorial Hospital Northwestern University durvalumab atezolizumab bilateral non-small cell lung cancer toripalimab nivolumab COPD cemiplimab colorectal cancer+4 more

…o underwent bilateral orthotopic lung transplantation (BOLT) at Northwestern Memorial Hospital (Sep 2021-May 2025) after at least one cycle of ICI therapy. Pa…

580 Phase 1 study of mitotic checkpoint inhibitor BAL0891 in combination with tislelizumab (anti-PD-1 antibody) in patients with advanced solid tumors

jitc · abstract · 2025-11-04 · 2 matching annotations

86.5%

Cancer Res 2025 BAL0891 tislelizumab triple-negative breast cancer TTK-CS-101

…2164. https://doi.org/10.1158/1538-7445.AM2025-2164Wang, et al. Cancer Res 2025;85(8_Supplement_1):2169. https://doi.org/10.1158/1538-7445.AM20…

582 First-in-human phase 1/2 study of the integrin αvβ8-blocking antibody CRB-601 in patients with solid tumors

jitc · abstract · 2025-11-04 · 2 matching annotations

80.1%

Cedars-Sinai Medical Center Stephenson Cancer Center CRB-601 ovarian cancer head and neck squamous cell carcinoma melanoma

…University Hospital Cleveland University Hospitals IRB 20241088 Cedars-Sinai Medical Center Cedars-Sinai Office of Research Compliance and Quality Improvem…

583 Intrathecal PD-1 inhibitor combined with pemetrexed for leptomeningeal metastases from solid tumors: preliminary results from a phase I/II study (NCT 06462222)

jitc · abstract · 2025-11-04 · 2 matching annotations

91.2%

Guangzhou Medical University Affiliated Huizhou Hospital pemetrexed non-small cell lung cancer solid tumors small cell lung cancer Intrathecal PD-1 inhibitor breast cancer involved-field radiotherapy leptomeningeal metastases+1 more

… Institutional Review Board of the Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, China (Approval number: 2024-KY-029-01). Informed con…